SCHEMBL6853036

SCHEMBL6853036

COc1ccc(OC)c(C(=O)C2CCCCC2c2ccc(OC)c(O)c2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.45
LMNA P02545 4/20 0.45
KDM4E B2RXH2 2/20 0.45
TUBB4A P04350 3/20 0.44
TUBB P07437 3/20 0.44
TUBA3C P0DPH7 3/20 0.44
TUBA1B P68363 3/20 0.44
TUBA4A P68366 3/20 0.44
TUBB4B P68371 3/20 0.44
TUBB3 Q13509 3/20 0.44
TUBB2A Q13885 3/20 0.44
TUBB8 Q3ZCM7 3/20 0.44
TUBA3E Q6PEY2 3/20 0.44
TUBA1A Q71U36 3/20 0.44
TUBA1C Q9BQE3 3/20 0.44
TUBB6 Q9BUF5 3/20 0.44
TUBB2B Q9BVA1 3/20 0.44
TUBB1 Q9H4B7 3/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6859994 0.93 TUBB4A (0.49) MAPTLMNAKDM4ETUBB4ATUBB
SCHEMBL7117399 0.92 LMNA (0.42) MAPTLMNAKDM4EMEN1KMT2A
SCHEMBL7119962 0.92 MAPT (0.42) MAPTLMNAKDM4ETUBB4ATUBB
SCHEMBL7122963 0.90 MAPT (0.48) MAPTLMNAKDM4EMEN1KMT2A
SCHEMBL7120205 0.89 MAPT (0.43) MAPTLMNAKDM4ETUBB1MEN1
SCHEMBL6860019 0.88 TUBB4A (0.51) MAPTLMNAKDM4ETUBB4ATUBB
SCHEMBL6853114 0.87 KDM1A (0.44) MAPTLMNAKDM4ETUBB4ATUBB
SCHEMBL6314925 0.87 KDM1A (0.42) MAPTLMNAKDM4EMEN1KMT2A
SCHEMBL6859799 0.85 TUBB4A (0.44) MAPTLMNAKDM4ETUBB4ATUBB
SCHEMBL6853125 0.85 TUBB4A (0.44) MAPTLMNAKDM4ETUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453783-A1 SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS Aventis Pharma S.A. (FR) 2004-09-08 EP disclosed
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2003-08-07 US disclosed
WO-2003048096-A1 SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS AVENTIS PHARMA S.A. (FR) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof ABL1, MCL1, AHR MAPT 4538/4885LMNA 3280/4885KDM4E 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.